Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Memantine hydrochloride tablets (yibeishen)

Treat moderate to severe Alzheimer's dementia. More role
App download minus 10 yuan
Common name:
Memantine Hydrochloride Tablet
Product No.:
B14202011991
Approval No.:
H20120268 (inquired by the State Drug Administration)
Jianke price:
¥475.00
Product specification:
10mg*28s
Manufacturer:
H. Lundbeck A / S (Denmark Lingbei pharmaceutical factory)
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Memantine hydrochloride tablets (yibeishen)
Main raw materials The main ingredients of this product are memantine hydrochloride: Chemical name: 1-amino-3,5-dimethyl amantadine hydrochloride Molecular formula: c12h21n · HCl Molecular weight: 215.77.
Main role Treat moderate to severe Alzheimer's dementia.
Product specification 10mg*28s
Usage and dosage This product should be prescribed by a doctor experienced in the diagnosis and treatment of Alzheimer's dementia and guide the use of patients. Treatment can only be started when the patient has a caregiver who supervises the patient's medication on time. Dementia should be diagnosed according to the current diagnostic criteria and guidelines. This product should be taken once a day at the same time every day, either on an empty stomach or with food. Adult: maximum daily dose 20mg. In order to reduce the occurrence of adverse reactions, the maintenance dose should be gradually reached by increasing the dose of 5mg per week in the first three weeks of treatment, as follows: the dose in the first week of treatment is 5mg per day (half a tablet each time), 10mg per day in the second week (one tablet each time, once a day), 15mg per day in the third week (one and a half tablets each time), and 20mg per day after the fourth week (two tablets at a time, once a day). Elderly patients: according to the results of clinical research, the recommended dose for patients over 65 years old is 20mg per day (two tablets per time, once a day) (see [elderly medication]). Patients with children and adolescents: since there is no data on the safety and effectiveness of this product for children and adolescents, it is not recommended to use this product for children and adolescents (see [medication for children]). Patients with renal insufficiency: for patients with mild renal insufficiency (creatinine clearance 50-80m1 / min), there is no need to adjust the dose. For patients with moderate renal insufficiency (creatinine clearance 30-49m1 / min) For patients with severe renal insufficiency (creatinine clearance rate 5-29m1 / min), the dose of memantine should be reduced to 10mg per day; if the patient can tolerate it well at least 7 days after the start of treatment, the dose can be increased to 20mg per day according to the standard dose adjustment scheme. For patients with severe renal insufficiency (creatinine clearance rate 5-29m1 / min), the dose of memantine should be 10mg per day. Patients with liver insufficiency: Patients with mild to moderate liver insufficiency (liver function grades child Pugh A and child Pugh b) do not need to adjust the dose. At present, there is no data on memantine applied to patients with severe liver insufficiency. This product is not recommended for patients with severe liver insufficiency.
manufacturing enterprise H. Lundbeck A / S (Denmark Lingbei pharmaceutical factory)
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Special personnel are assigned to manage and ensure product inventory.

[drug name] Memantine hydrochloride tablets (yibeishen)

[common name] Memantine Hydrochloride Tablet

[specification and model] 10mg*28s

[manufacturer] H. Lundbeck A / S (Denmark Lingbei pharmaceutical factory)

[drug type] Western medicine

[approval No.] H20120268

[validity period] 48 months

[functional indications] Treat moderate to severe Alzheimer's dementia.

[usage and dosage] This product should be prescribed by a doctor experienced in the diagnosis and treatment of Alzheimer's dementia and guide the use of the patient. The treatment can be started only when the patient has a caregiver who supervises the patient's medication on time. Dementia should be diagnosed according to the current diagnostic standards and guidelines. This product should be taken once a day at the same time every day, either on an empty stomach or with food. Adults: the maximum daily dose is 20mg. In order to reduce the occurrence of adverse reactions, the maintenance dose should be gradually increased by 5mg per week in the first three weeks of treatment, as follows: the dose in the first week of treatment is 5mg per day (half a tablet each time), 10mg per day in the second week (one tablet each time, once a day), and 15mg per day in the third week (one and a half tablets each time) , after the fourth week, take the recommended maintenance dose of 20mg per day (two tablets per time, once a day). Elderly patients: according to the results of clinical research, the recommended dose for patients over 65 years old is 20mg per day (two tablets per time, once a day) (see [elderly medication]). Patients with children and adolescents: since there is no data on the safety and effectiveness of this product for children and adolescents, it is not recommended to use this product for children and adolescents (see [medication for children]). Patients with renal insufficiency: for patients with mild renal insufficiency (creatinine clearance 50-80m1 / min), there is no need to adjust the dose. For patients with moderate renal insufficiency (creatinine clearance rate 30-49m1 / min), the dose of memantine should be reduced to 10mg per day; If the patient is well tolerated at least 7 days after the start of treatment, the dosage can be increased to 20mg / day according to the standard dose adjustment scheme. For patients with severe renal insufficiency (creatinine clearance 5-29m1 / min), the dose of memantine should be 10mg per day. Patients with liver dysfunction: Patients with mild to moderate liver dysfunction (child Pugh A and child Pugh b) do not need to adjust the dose. At present, there is no data on the application of memantine in patients with severe liver dysfunction. This product is not recommended for patients with severe liver insufficiency.

[adverse reactions] In the clinical study of patients with moderate to severe Alzheimer's dementia, the memantine treatment group includes 1784 patients and the placebo group includes 1595 patients. The total incidence of adverse events of this product is equivalent to that of placebo, and the adverse events are usually mild to moderate. The incidence of common adverse reactions in patients treated with memantine was higher than that in placebo group: dizziness (6.3% vs.5.6%), headache (5.2% vs.3.9%), constipation (4.6% vs.2.6%), drowsiness (3.4% vs.2.2%) and hypertension (4.1% vs.2.8%). The following table lists the cumulative adverse events observed in clinical studies since the global initial marketing of this product. In each group, adverse events were ranked in descending order of severity. (see instructions for details)

[precautions] Patients with epilepsy, history of convulsion or epilepsy susceptible constitution should be cautious when taking memantine. Combination with N-methyl-D-aspartate (NMDA) receptor antagonists such as amantadine, ketamine or dextromethorphan should be avoided. These drugs are the same as the receptor system of memantine, which may increase the incidence of adverse drug reactions (mainly related to the central nervous system) or aggravate adverse reactions (see [drug interaction]). Patients with elevated urine pH must be closely monitored when taking this product. Factors that increase urinary pH include sudden changes in dietary structure, such as changing from meat to vegetarian, or taking a large amount of alkaline gastric acid buffer. In addition, in patients with severe urinary tract infection caused by renal tubular acidosis (RTA) or denatured bacilli, the pH value of urine will also increase (see the "elimination" section of [pharmacokinetics]). Because most clinical studies have not studied the recent occurrence of myocardial infarction and non compensatory congestive heart failure (nyhaiii)- 4) Or hypertension patients who have not been effectively controlled. Therefore, these patients have limited data on the application of memantine, so they should be closely observed when taking this product. Moderate to severe Alzheimer's dementia usually causes damage to driving and mechanical operation ability, and memantine may have a mild to moderate impact on the patient's response ability. Therefore, patients taking this product should be particularly careful when driving or operating machinery. Excipients: This product contains lactose monohydrate. This product should not be used in patients with rare genetic lactose intolerance, lack of Lapp lactose lyase or impaired glucose galactose absorption.

[taboo] It is forbidden for those who are allergic to the active ingredients or their excipients of this product.

[listing Permit Holder] H. Lundbecka / S (Denmark Lingbei pharmaceutical factory)

[packaging unit] box

[main ingredients] The main ingredients of this product are memantine hydrochloride: Chemical name: 1-amino-3,5-dimethyl amantadine hydrochloride Molecular formula: c12h21n · HCl Molecular weight: 215.77.

[character] This product is a white to off white, double-sided raised oval film garment with a notch on both sides.

[applicable population] adult

[medication for pregnant and lactating women] Pregnancy: at present, there is no clinical data of this product for pregnant patients. Animal experiments show that the administration of memantine equivalent to or slightly higher than the dose level of human medicine may lead to intrauterine growth retardation (see [pharmacology and toxicology]). The potential danger to human body is not clear. This product should not be taken during pregnancy unless specifically required. Lactation: it is not clear whether memantine can be secreted from breast milk, but considering the lipophilicity of memantine, this possibility exists. Therefore, lactating women should stop breastfeeding when taking this product.

[medication for children] There is no data on the efficacy and safety of this product for children and adolescents.

[medication for elderly patients] The recommended dose for patients over 65 years old is 20mg per day (two tablets per time, once a day).

[storage] Sealed and stored at room temperature.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Memantine hydrochloride tablets (yibeishen)

    ¥475.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!